Archive | February, 2013

Update on New Prodromal Cohort Added to PPMI

This March, the Parkinson?s Progression Markers Initiative (PPMI) will launch a new study arm to enroll and follow a prodromal Parkinson?s disease (PD) cohort.   Defining a pre-diagnostic or prodromal phase for PD presents both an immediate challenge ? how to reliably identify individuals during this prodromal period at high risk to phenoconvert to PD ? […]

Continue reading...

Researchers Publish First Paper Using PPMI Data

Daniel Weintraub, MD, and a team at the University of Pennsylvania publish the first paper using PPMI data demonstrating that Parkinson's itself does not confer a higher risk for ICDs, supporting other research that suggests the high prevalence of ICDs in people with PD is related to Parkinson's medications, and not the disease itself.

Continue reading...

PPMI Scientific Leadership to Present at AD/PD 2013 in Florence, Italy

AD/PD 2013 will take place in Florence, Italy from March 6th to the 10th. Three members of the PPMI Steering Committee will be presenting on the PPMI Baseline Cohort and various imaging modalities included in the study.

Continue reading...

Dr. John Q. Trojanowski to Present on PPMI at the International Conference on Alpha-Synuclein in Parkinson?s Disease and Related Neurodegenerative Diseases

Dr. Trojanowski, PI of the PPMI Bioanalytics Core will present on PPMI during the Biomarkers session at the International Conference on Alpha-Syunclein in Parkinson?s Disease on March 3, 2013 at 9:45 AM in Dubai. His talk will focus on the early Synuclein analyses that have been done in PPMI and preliminary findings on a subset of PPMI samples.

Continue reading...